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erythropoeitin enhances recovery of lost memory
function after global cerebral ischemia in the rat
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Background: Erythropoietin (EPO) and its covalently modified analogs are neuroprotective in various models of
brain damage and disease. We investigated the effect on brain damage and memory performance, of a continuous
3-day intravenous infusion of EPO, starting 20 min after a transient 10 minute period of global cerebral ischemia in
the rat.
Results: We found no effect on selective neuronal damage in the CA1 region of the hippocampus, neocortical
damage and damage to the striatum assessed at 7 days after ischemia. Also, no differences were observed in
sensori-motor scores between EPO treated and saline treated ischemic animals. In contrast, memory performance
was significantly improved in the EPO treated group. Saline treated injured animals (n = 7) failed in a test assessing
recovery of spatial memory (6/6 and 5/6), while EPO treated animals had few and none failures (0/7 and 1/7).
Conclusion: We conclude that although post-ischemic treatment with EPO is not neuroprotective in a model of
cardiac arrest brain ischemia, its markedly positive effect on brain plasticity and recovery of memory function
warrants consideration as treatment of cardiac arrest patients.Background
Erythropoietin (EPO), a cytokine and growth factor and
one of the principal modulators of erythropoiesis [1,2],
has recently been recognized for its broad applicability
in medicine [3]. The EPO gene is regulated by hypoxia
inducing factor (HIF), where it stimulates erythropeoisis
and proliferation of parenchymal cells, by acting on the
EPO receptor (EpoR) coupled to PI3-kinase, JAK/STAT
and NF-κB pathways [4-6]. In the brain, EPO is neuro-
protective and has also brain restorative properties in
different models of acute neuronal death and neurode-
generative diseases, through effects on neurons and as-
trocytes by multimodal actions [7]. In models of stroke,
spinal cord injury, traumatic brain injury, brain edema,
EPO is clearly neuroprotective [8-11]. In models of focal
ischemia in the rat EPO is both protective, i.e. decreases
infarct size but also enhances brain plasticity in rat and* Correspondence: tadeusz.wieloch@med.lu.se
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reproduction in any medium, provided the ormice [12]. Here the carbamylated form of EPO, CEPO,
that lacks erythropoietic activity, can be administered up
to 7 days after MCAO with a significant improvement of
sensori-motor function but without affecting infarct size.
This strongly suggests that EPO enhances plasticity when
administered in the subacute phase after stroke. Indeed
EPO also stimulates cognition and enhances LTP [13].
In models of global ischemia, mimicking cardiac ar-
rest, EPO is protective though only if applied prior to or
20 minutes after ischemia and only when administered
through the intracerebroventricular (i.c.v.) route [14]. If
provided intravenously within 5 minutes after recovery
of spontanuous cardiac activity and then subsequently at
1 and 3 days of recovery after the ischemic insult, no
beneficial effects are seen on neither morphological out-
come, markers of cell death or gross sensori-motor
scores [15]. The aim of the present investigation was to
study the effect of EPO treatment as a continuous intra-
venous administration in a model of global ischemia
starting the treatment 20 minutes after reperfusion. We
choose a route and time of administration that can be
expected in a possible treatment of cardiac arrestLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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model of global cerebral ischemia [16] and assessed the
histological outcome and sensori-motor and memory
performance after ischemia.Methods
Surgical procedures
The animal experiments were performed on male Wistar
rats, weighing 300-350 g (Møllegaard’s Breeding Center,
Copenhagen, Denmark), which were fasted overnight
with free access to tap water. The experiments were ap-
proved by the Malmö/Lund Ethical Committee on Ani-
mal Experiments and were in accordance with the
guidelines of the National Institute of Health (NIH). All
efforts were made to minimize animal suffering and to
reduce the number of animals used.
The two-vessel occlusion (2-VO) model of global cere-
bral ischemia was used [16]. In brief, the animals were ini-
tially anaesthetized with 3.5-4% isoflurane in N2O/O2
(70:30) and then intubated and connected to a small ani-
mal respirator. The isoflurane concentration was reduced
to 1.5% for the remainder of the surgery. The tail artery
and vein were cannulated for blood pressure recordings,
blood sampling and drug infusions. The right jugular vein
was used to insert a soft silastic catheter into the superior
caval vein for rapid withdrawal of blood and reduction of
the blood pressure to 45–50 mmHg during ischemia. Both
common carotid arteries were dissected and encircled
with loose ligatures. In addition, EEG electrodes were
placed into the temporal muscles and EEG activity
recorded. Thereafter, both common carotid arteries were
reversible clamped for 10 minutes. At the end of surgery,
isoflurane concentration was reduced to 0.5-1% and the
ventilation and O2 supply was adjusted to an arterial PCO2
of 35–40 mmHg and a PO2 of close to 100 mmHg. Hep-
arin (90 IU.kg-1) was given prior to the first blood gas
measurement. During the experiment, animals were para-
lyzed with vecuronium bromide (2 mg.h-1). The animals’
head and body temperature were kept close to 37°C using
a heating lamp and a thermostat-regulated pad.
Immediately after ischemia, 0.5 ml of a 0.6 mol/L
NaHCO3 solution was given intravenously to neutralize
systemic acidosis, and isoflurane supply was disconti-
nued. When the animals regained spontaneous breathing
they were extubated and disconnected from the respir-
ator and were then housed in cages with free access to
tap water and pellet food. Sham-operated animals were
treated in the same way as those in the ischemia group
except for the occlusion of the carotid arteries and the
reduction of blood pressure. In total 23 rats were ope-
rated, thereof 2 rats were excluded immediately after
surgery due to surgery problems, one animal died on
day 3 after surgery.Randomization, EPO administration and EPO analysis
Every other animal was randomized into the treatment
groups and received either an intravenous bolus injection
of EPO (Neorecormon, Roche, Switzerland) immediately
after surgery calculated based on the following equation:
80 IU multiplied with the volume of distribution (VD;
0.057 mL/g BW). Thereafter, maintenance intravenous
infusion was performed at 160 IU per hour via an osmotic
minipump (mini-osmotic alzet pump2001 D) for 72 h or
an intravenous saline injection immediately after surgery
and saline infusion via an osmotic minipump for addi-
tional 72 h (mini-osmotic alzet pump 1003D). Serum was
analyzed for EPO 10 to 15 minutes after the bolus injec-
tion and 5 and 72 h after the surgery using an automated
ELISA system (QuantikineW IVDW ELISA, R&D Systems,
UK).Histopathological procedures
For histopathological analyses, animals were re-
anaesthetized with 3.5% isoflurane, tracheotomized,
artificially ventilated, and perfusion-fixed with phosphate-
buffered 4% formaldehyde after 7 days of reperfusion. The
brains were allowed to fix in situ for one hour and were
then removed, dehydrated, and embedded in paraffin. The
paraffin embedded brains were sectioned at 5 μm, and
stained with celestine blue and acid fuchsin. Sections were
deparaffinized, incubated in celestin blue solution (0,5%)
for 1 minute and after washing with acetic acid incubated
in acid fuchsin solution (1%) for 1 minute. After dehydra-
tion and mounting, brain damage was quantified by visual
counting of intact violet-stained neurons in a blinded
manner according to Nellgard and Wieloch [17]. Unda-
maged neurons, which had an intact nucleus and stained
violet, were counted in three defined fields, each 400 μm
in length, of the CA1 subsector of the dorsal hippocampus
(3.8 to 4 mm caudal to bregma): the medial, hipp (1), the
middle, hipp (2), and the lateral, hipp (3) CA1 (at the
border to CA3). Cortical (Cx) damage was assessed in a
circular area of 400 μm in diameter of the temporal cortex
which is most sensitive area in the model of global ische-
mia. Striatal (Str) damage was assessed as neuronal score:
score 0 - no damage, score 1 - damage to dorsal striatum
or ventral striatum, 2- both ventral and dorsal rim, 3- entire
striatum affected.TUNEL assay
The assay was performed according to the manufac-
turers instructions using the protocol for paraffin-
embedded tissue sections (Roche Diagnostics GmbH,
Germany). TUNEL positive cells were counted from the
entire CA1 region of the hippocampus (approximately
3.8 to 4 mm caudal to bregma) and presented as abso-
lute numbers.
Undén et al. BMC Neuroscience 2013, 14:27 Page 3 of 8
http://www.biomedcentral.com/1471-2202/14/27Behavioral tests
This test combines a sensori-motor test and a memory
test of the T-maze type [18]. The rotating pole test mea-
sures coordination and integration of movements [19].
Rats traverse an elevated wooden pole (elevation 700
mm, diameter 40 mm, length 1500 mm) rotating at a
speed of 10 rpm to the left or right. Prior to ischemia
the animals are trained several days before ischemia
until they can cross the pole onto a platform and enter
the home cage. The home cage, made of transparent
plexi-glas with an entrance opening at the left edge, is
placed in front of the platform at the end of the pole. A
cardboard wall is placed perpendicular to the cage wall,
immediately to the right of the rotating pole with the en-
trance accessible, but not seen by the rat. This part of
the test requires retention of memory. At 7 days after
ischemia, each animal was tested twice, while recorded
by a video camera. A score (0 to 6) was subsequently
assigned to each performance. 0 means falling off the
pole immediately; 1 means unable to traverse the pole; 2
means falling off the pole while crossing; 3 denotes
crossing the pole while slipping and jumping with the







vehicle 123.4 ± 22.1 125.1 ± 2
EPO 111.0 ± 9.7 116.75 ±
temperature (°C) vehicle 37.82 ±
EPO 37.49 ±
pCO2 (kPa) vehicle 4.82 ± 0.96 5.55 ± 1
EPO 5.26 ± 1.45 5.75 ± 1
pO2 (kPa) vehicle 17.37 ± 2.57 17.05 ± 3
EPO 17.86 ± 2.64 17.69 ± 2
pH vehicle 7.43 ± 0.07 7.34 ± 0
EPO 7.43 ± 0.07 7.43 ± 0
HCO3
- vehicle 24.32 ± 0.87 26.02 ± 2
EPO 25.88 ± 1.39 27.16 ± 1
Hb (g/l) vehicle 159.8 ± 6.61 148.0 ± 1
EPO 149.57 ± 8.1 133.86 ±
HCT (%) vehicle 48.9 ± 2 45.4 ± 3
EPO 45.0 ± 3.2 41.8 ± 2
glucose (mmol/l) vehicle 5.88 ± 2.7
EPO 7.05 ± 1.6
treatment before occlusion
body weight (g) vehicle 332.0 ± 8.3
EPO 345.0 ± 18.3
Data are presented as means ± standard deviation at the time of recirculation. Stati
observed between the treatment groups. *p = 0.0002 vs vehicle treatment before oslips; 5 means crossing with few slips; 6 indicates cross-
ing with no foot slips. Score 5–6 is considered as normal
performance. Correct or failed entry into the homecage
were registered.
Statistical analysis
Differences in the number of cells in the hippocampus and
cortex in saline and EPO treated rats were analyzed by the
Students t-test. Effects of EPO treatment on neuronal sur-
vival in the striatum were analyzed by the Mann–Whitney
test. Individual physiological parameters between saline
and EPO treated animals at the same time point were ana-
lyzed by the Students t-test. Physiological parameters
within a treatment group were analyzed by ANOVA for
repeated measurements and Dunnetts T3 posthoc test. Be-
havioral tests were anlyzed by the Mann–Whitney test.
Statistical analyses were performed using IBM SPSS Statis-
tics 20.0 (IBM Svenska AB, Sweden).
Results
Physiological parameters and serum EPO levels
Table 1 shows physiological data obtained from rats of








1.8 123.7 ± 14.3
15.3 103.3 ± 11.8
0.3 38.05 ± 0.5
0.9 37.62 ± 0.5
.01 4.73 ± 0.6 5.77 ± 0.41 5.92 ± 0.48
.1 5.28 ± 1.89 5.79 ± 0.63 6.35 ± 0.66
.99 16.67 ± 3.08 16.84 ± 5.33 15.15 ± 2.05
.58 17.61 ± 3.05 17.4 ± 4.53 15.23 ± 2.77
.15 7.47 ± 0.06 7.42 ± 0.04 7.44 ± 0.02
.06 7.46 ± 0.1 7.43 ± 0.03 7.43 ± 0.05
.72 26.27 ± 1.76 27.1 ± 1.69 29.0 ± 0.7
.38 27.68 ± 0.92 27.60 ± 1.05 29.36 ± 1.53
1.79 152.0 ± 9.12 145.57 ± 9.45 125.67 ± 4.73*
9.99 147.0 ± 5.24 141.67 ± 13.49 132.46 ± 27.52
.5 46.6 ± 2.8 44.6 ± 2.8 38.7 ± 1.5*





stical differences are indicated. No indications are given if no difference was
cclusion.
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of hemoglobin and hematocrit was observed in saline
treated rats but remained stable in EPO treated rats after
ischemia. Measurement of serum EPO levels revealed a
fast increase after bolus injection of EPO into the jugular
vein. Levels remained detectable until the end of the treat-
ment period three days after ischemia (Figure 1).Brain damage
Brain damage was assessed in the hippocampal CA1 re-
gion, the cortex and striatum. In control animals neu-
rons appear as large violet stained cells with a diameter
of 30-50 μm and with a large owls eye-like nucleus.
Damaged neurons were triangular shaped red-pink
stained, with condensed dark nuclei as described previ-
ously [20]. Ten minutes of global brain ischemia induces
a mean 80–90 percent damage to the dorsal aspect of
the CA1 region with some animals with less damage
(40-50%). Damage to cortex is less pronounced at this
short time of ischemia, and hence few damaged neurons
were detected. In striatum, damage is variable affecting
the dorsal and ventral part as well as the entire striatum
and therefore sensitive to any modulation of neuronal
survival by EPO. Statistical analysis did not reveal any
significant difference between saline treated (n = 7) and
EPO treated (n = 9) animals on cell survival (CA 1 re-
gion) or cell death (striatum and cortex) (Figure 2). In
addition, EPO treatment did not affect the number of
apoptotic cells in the CA1 region of the hippocampus
(Figure 3). Moreover, no TUNEL positive cells were
found in the neocortex and striatum. Data show that de-
layed cell death is induced in the CA1 region of the
hippocampus after global ischemia, without being af-














Figure 1 Serum EPO concentrations after EPO treatment. Serum
EPO levels measured after bolus injection of 1600 IU and 5 and 72
hours after EPO treatment (see Methods section). Data are presented
as mean ± SEM and obtained from 9 rats.Sensori-motor and memory performance
All experimental animals scored 5–6 on the rotating
pole part of the test, which is considered normal, and
also obtained in sham operated rats. In the memory
challenging part of this test, saline treated animals gene-
rally failed to enter the home cage. When the pole was
rotating to the left 4 out of 7 animals failed when the
pole was rotating with 3 rotations per minute (rpm) and
6 out of 7 animals failed at 10 rpm, respectively, and
when rotated to the right, 2 out of 6 succeeded finding
the entry at 10 rpm. In contrast, all EPO treated animals,
7 out of 7, successfully and directly entered the cage
when the pole rotated to the right, and 6 out of 7 when
the pole rotated to the left (Figure 4). The test was
performed repeatedly during test sessions. Therefore, the
results indicate a spatial learning deficit in rats treated
with saline after ischemia.
Discussion
This study was conducted to investigate neuroprotective
effects of EPO treatment in rats subjected to global is-
chemia and sought at identifying if the treatment is asso-
ciated with an improvement of sensorimotor and
memory function. We show that EPO has no influence
on neuronal survival and delayed neuronal cell death in
the CA1 region in the hippocampus, cortex and striatum
of rats subjected to ischemia but treatment significantly
preserved memory function.
Pharmacokinetics of EPO delivery and long-term effects
on blood parameters
Administration of EPO by continuous infusion ensured
serum levels similar to those found in animals subjected
to intermittent hypoxia [21]. Interestingly, we also ob-
served a reduction of hemoglobin and hematocrit in sa-
line treated animals but not in EPO treated rats within
the first 72 hours after ischemia. Postischemic EPO
treatment has led to increased erythropoiesis compen-
sating the loss of red blood cells related to the ischemia
model. Thus, it might be anticipated that beneficial ef-
fects of EPO on memory function might be related to
the prevention of postischemic anemia. Deleterious ef-
fects of anemia on stroke outcome have been described
in patients [22], hence, previous studies also have shown
that EPO mediated effects on memory function are inde-
pendent from its effects on the erythropoietic system
[23].
Effects of EPO on neuronal damage after global ischemia
Our results confirm those of Popp and colleagues [15]
showing lack of neuroprotective efficacy of EPO in a rat
model of cardiac arrest imposing a 8 minutes ischemic
insult to the brain. In addition, we did not find any
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Figure 2 Assessment of neuronal survival after global ischemia. Neuronal damage in three areas (lateral (1), mid (2) and medial (3)) of the
dorsal rat hippocampus (hipp) expressed as percent of undamaged cells obtained in controls, the neocortex (Cx) and in the striatum (Str) as
damage scores. Each dot represents an individual animal. Animals were treated with either vehicle or EPO infusion of 3 days. Damage was
assessed on day 7 after 10 minutes of global cerebral ischemia. No significant difference between vehicle or EPO treated groups was found.
Statistical analysis: hippocampus and cortex – Students t-test; striatum - Mann–Whitney test. Abbreviations: l –left, r – right, sal – saline.
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obtained when EPO was administered intraventricularly
(icv) prior to or 20 minutes after global ischemia the rat
[14] or immediately upon reperfusion in the gerbil [25].
The neuroprotective effect seen after icv injections of EPO
might suggest a mechanism active early (hours) of reper-
fusion. The present model is amenable to neuroprotection.
The most robust neuroprotection is provided by mild
hypothermia (body temperature 33°C) in the hippocampus








Figure 3 Effect of EPO treatment on delayed cell death after global is
no TUNEL positive cells in the cortex and striatum. TUNEL positive pyramid
both treatment groups. (B) Quantification of TUNEL positive cells in the en
with the median (black line), p = 0.69, Students t-test.reperfusion, presumably acting on multiple detrimental
mechanisms. Pharmacological neuroprotection, which is
not due to concomitantly induced body hypothermia [26],
has a more narrow therapeutic time window. For example,
cyclosporin A and the AMPA-receptor blocker NBQX are
neuroprotective when administered within the first 30
min to 2 hours of reperfusion but not later [27].
Since EPO has been proposed to act both on neurons
and astrocytes, by preventing apoptosis and stimulating




















chemia. (A) Representative micrographs of coronal sections showing
al neurons were observed in the CA1 region of the hippocampus in

















sign 0.026 0.209 0.026 0.209 0.383
Figure 4 memory retention test. (A) Design of the test: animals crossed a rotating pole at 0, 3 or 10 rpm either to the right or to the left. At
the end of the pole the rat were allowed to find a hidden entrance and the successfull (1) or failed (0) entries noted. (B) Scores of rats subjected
to ischemia and treated either with saline (n = 7) or EPO (n = 7) for 3 days. Mann–Whitney test, individual significances are shown in the Figure.
Abbreviations: l –left, r – right, sal – saline, sign - significance.
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providing protection. To what extent EPO treatment
contributes to the release of pro-inflammatory cytokines
and other inflammatory actions of microglia/macro-
phages after ischemia has to be addressed in future stud-
ies [29,30]. Evidently, the EPO targeted detrimental
mechanisms do not appear to contribute to selective and
delayed neuronal death after global ischemia. In con-
trast, EPO treatment effectively prevents pan-necrosis of
the penumbra tissue after focal ischemia.
Effects of EPO on sensori-motor and memory functions
Global ischemia is known to induce relative subtle be-
havioral deficits. Here we present a novel and simple test
for combined non-associative factors (sensori-motor def-
icit), with memory retention. Loss of memory function
in the 2-VO model of global ischemia has earlier been
seen in the radial maze-tests and Morrize water maze
test, probing spatial learning and retention of working
memory [31]. Our data showing retained “cognitive”
function in animals injured by global ischemia is stri-
king. This is in line with the findings that EPO enhances
LTP and memory functions in naive rats [13] and im-
proves memory function in a model of Alzheimers di-
sease [32] and long-term spatial memory deficits and
brain injury following neonatal hypoxia-ischemia in rats
[33]. In that context high expression of EpoR in pyram-
idal neurons in the cortex and hippocampus has been
associated with higher cognitive functions [34]. Erythro-
poietin treatment also increased the hippocampal res-ponse during picture encoding and retrieval in human
[23] and increased expression of the EpoR has been
found in postmortem analyses of patients with
Alzheimers disease [35].
In focal ischemia treatment with EPO 24 h after reper-
fusion enhances recovery of neurological function with-
out affecting infarct size [36]. This suggests that EPO
enhances recovery of transmission that is lost during
brain ischemia. The recovery enhancing action of EPO
could be an effect on synaptic function of pre-existing
synapses on surviving neurons, or by formation of new
synapses on surviving neurons. Since the animals
learned the task prior to ischemia, our study design
probes retention of memory traces on existing synapses,
rather than formation of new synapses, which would
require a period of re-learning. Since damage is almost
70-90% in the dorsal hippocampus, we are inclined to
support the notion that EPO prevents the loss of mem-
ory in the ventral parts of hippocampus, and enhances
LTP in this region.Conclusions
We conclude that intravenous EPO administration after
global ischemia does not protect against ischemic brain
damage, but protects against loss of synaptic function
important for working and spatial memory. We believe
our data have important clinical implications, and
propose that EPO treatment may be beneficial for the
retention of cognitive functions of the cardiac arrest
patient.
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